Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampicillin + netilmicin is a combination of two antibiotics used primarily for the treatment of serious bacterial infections, especially those caused by enterococci and other susceptible organisms. Ampicillin is a beta-lactam antibiotic (penicillin class) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death[3][5]. Netilmicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA in bacteria[9]. The combination exhibits synergistic bactericidal activity against many strains of Enterococcus species (notably Enterococcus faecalis), as well as enhanced activity against certain Gram-negative pathogens. This synergy makes it particularly useful in severe infections such as endocarditis caused by enterococci[4][9]. Both drugs are administered parenterally due to poor oral absorption (netilmicin) or for severe infection (ampicillin). Monitoring for nephrotoxicity and ototoxicity is important due to the aminoglycoside component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + netilmicin.